Business Wire

Boehringer Ingelheim R&D Pushes to Transcend Disease Boundaries

Del

Family-owned pharmaceutical company Boehringer Ingelheim today presented its latest pipeline updates at a Research & Development press conference entitled ‘Transcending Disease Boundaries’, at its global headquarters in Ingelheim, Germany. The company’s R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted). With a high percentage of first-in-class and breakthrough potential drug candidates, Boehringer Ingelheim continues the successful implementation of its R&D strategy.

Boehringer Ingelheim is committing more than €20 billion to Research & Development for human pharmaceuticals by 2025. In the past four years, the company received 14 regulatory approvals in several new indications, including four new molecular entities and four breakthrough designations by the US Food and Drug Administration.

“The most ambitious goal for researchers is to achieve a medical breakthrough for patients from our over 80 clinical and pre-clinical projects. Some 65% of our drug pipeline candidates already have breakthrough and/or first-in-class potential, and we aim for even more” said Dr Michel Pairet, Member of the Board of Managing Directors, responsible for Boehringer Ingelheim’s Innovation Unit, “Transcending disease boundaries is about looking at R&D with fresh eyes.”

To fulfil such aspirations, Boehringer Ingelheim embraces risks to dig deep into the mechanisms of diseases, to integrate the latest scientific and technological advances, and to work with the best partners to discover and deliver new medicines.

“Our worldwide team of 8,000 scientists, medical doctors and other contributors is truly motivated by our pipeline, its progress and what this could mean for patients.” commented Dr Christopher Corsico, Chief Medical Officer, Boehringer Ingelheim. “With ongoing work on a first-in-class inhibitor targeting inflammatory skin and bowel diseases, transformative oncology candidates, a promising schizophrenia prevention strategy and major indications for two of our blockbusters, Ofev® in lung fibrosis and Jardiance® in chronic kidney disease and chronic heart failure, we look forward to bringing years of health and improved quality of life to millions of people.”

To support and complement its own R&D, Boehringer Ingelheim is increasing the emphasis on external collaborations and expanding the community of innovation partners. The company currently works with over 70 innovative partners in universities, scientific institutions and biotech companies.

“Our long-lasting relationships with our partners are built on respect, empathy, trust and passion – values which foster an environment where synergies are realized, resulting in the potential for faster and better results.” said Dr Michel Pairet. “Our long-term, unwavering commitment to researching and developing new medicines will bring the transformative medicines that patients need.”

Highlights of Latest Boehringer Ingelheim Pipeline Progress

Immunology

In Immunology Boehringer Ingelheim’s IL-36 receptor inhibitor has the potential to transform the standard-of-care for patients with immune-mediated diseases.

BI 655130, a new biological entity and first-in-class IL-36 receptor antibody, has shown strong efficacy in early clinical testing with a single dose in patients affected by Generalized Pustular Psoriasis. These results support a broad potential in multiple inflammatory diseases.

Trials are underway in further immune-mediated diseases of the skin and intestine including Palmo-Plantar Pustulosis, Ulcerative Colitis, Crohn’s Disease, and other chronic inflammatory conditions.

Oncology

Boehringer Ingelheim is exploring therapies that target tumour cells directly in pathways so far ‘undrugged’. In Immune Oncology, the research teams are “turning up the heat on cancer” with therapies that activate the abilities of the patient’s own immune system and by bringing together smart and highly promising combinations of both types of therapies.

We are advancing combinations of immune-cell targeted therapies e.g. cancer vaccines, oncolytic viruses and T-cell engagers, as well as immunogenic cell death inducers such as our SMAC mimetic with BI 754091, a PD-1 checkpoint inhibitor.

In cancer cell directed projects, Boehringer Ingelheim’s oncology research portfolio includes more than 10 clinical-stage assets. We are working on new drug candidates in pathways such as KRAS, WNT and p53, and will move towards clinical trials for many of these in the next 12-24 months.

Central Nervous System

In CNS, Boehringer Ingelheim has expanded its PDE9 inhibition research programs to the prevention of relapse in schizophrenia and also in the prevention of first episode psychosis.

Boehringer Ingelheim’s research approach in CNS is taking a courageous “against the current” approach. The focus is on understanding how underlying malfunctions in brain circuitry manifest in specific symptoms and traits of mental illnesses. This is key to going beyond the current disease classifications which do not reflect the underlying disease mechanisms.

Boehringer Ingelheim investigates a range of mental disorders such as schizophrenia, Alzheimer’s disease and depression.

Fibrosis (Respiratory and Cardiometabolic Diseases)

Based on the pathophysiological and mechanistic parallels of fibrotic diseases, Boehringer Ingelheim is investigating its compound nintedanib in a wide spectrum of fibrosing Interstitial Lung Diseases (ILDs).

Two Phase III clinical trials are exploring the efficacy and safety of nintedanib (OFEV®) in Systemic Sclerosis ILD (SSc-ILD) and Progressive Fibrosing ILD (PF-ILD). The SENSCIS study has completed enrolment and may end in December 2018. The INBUILD study is likely to complete enrolment in Q2 2018.

In NASH, another fibrotic disease affecting the liver, Boehringer Ingelheim applies its deep understanding of the metabolic, inflammatory and fibrotic components of the disease and is investigating a frontrunner compound, an AOC3 inhibitor, in a Phase II clinical trial.

Cardiometabolic Diseases

In Cardiometabolic diseases, Boehringer Ingelheim is building on the strength of the results of the EMPA-REG OUTCOME® trial to explore the potential benefits of empagliflozin (JARDIANCE®1) beyond diabetes. Boehringer Ingelheim is investigating the potential of empagliflozin to protect patients with and without diabetes from the risk of chronic kidney disease and chronic heart failure.

Phase III studies are underway investigating the effects of empagliflozin in patients with Chronic Kidney Disease (CKD) and in patients with Chronic Heart Failure (CHF). The EMPA-KIDNEY and EMPEROR HEART FAILURE studies are expected to read out between 2019 and 2020.

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com

1 Jardiance® is jointly marketed by Boehringer Ingelheim and Eli Lilly and Company.

Contact information

Boehringer Ingelheim Corporate Center GmbH
Dr. Reinhard Malin
Head of Communications, Innovation Unit
Media + PR
Phone: +49 6132 77-90815
press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

myPOS Presented with Best POS Innovation Award by the Merchant Payment Ecosystem21.2.2019 14:57:00Pressemelding

myPOS, one of the fastest growing European payment providers was handed the Best POS Innovation/POS Software Payment Applications award for 2019 by the Merchant Payment Ecosystem (MPE) at a Gala Dinner ceremony in Berlin last night. Being known for offering instant settlement and no-monthly-fees model to SMEs across Europe, myPOS provides a range of innovative features on its payment devices, some of which include Tipping, Payment Request, Top-up and GiftCards. In addition, myPOS merchants are entitled to a whole range of subscription-free, value-added services such as Virtual MO/TO, PayLinks and PayButtons, Checkout module with the most popular shopping carts and more. myPOS clients are also given the opportunity to manage their funds with a free online account and a unique banking platform. The company got nominated in two categories: Best POS Innovation and Best Acquirer of the year, but ultimately won the Best POS Innovation award. "We accept this award with gratitude and appreciat

New Release Crea Records: "ABBA We Love You Forever"21.2.2019 14:44:00Pressemelding

Not many people on this earth can say that they have never heard of ABBA. In addition to the wonderful voices of Agnetha Fältskog and Anni-Fried Lyngstad, the musicians, Björn Ulvaeus and Benny Andersson have written the most wonderful songs, not only composed with charm and elegance, but also so breathtakingly beautiful and unforgettable that they will always resonate. For the Danish singer, BILLBOARD Hot 100 artist, composer and lyricist, Lecia Jonsson, ABBA has been much more than an inspiration. Lecia shared the same melodic universe as ABBA, making her mark with many records as part of duo LECIA & LUCIENNE. Later, as part of another duo, LABAN, Lecia entered BILLBOARD HOT 100 in the United States, had releases in 48 countries worldwide, and sold more than 1.5 million albums. Lecia’s identity is formed by her pure voice and her great sense for writing unique songs filled with a great melodic substance. If anyone should write a song to honour ABBA’s music, Lecia is definitely the pe

Ultivue Expands Global Presence with Opening of European Subsidiary, Ultivue EMEA Srl21.2.2019 14:30:00Pressemelding

Ultivue, a developer of tissue biomarker identification and quantification assays for pathology and translational research labs, today announced that it has expanded its commercial footprint with a wholly-owned European subsidiary and appointed Luigi Pirovano as General Manager. Mr. Pirovano is an international executive with significant experience managing European Diagnostics and Life Science operations and will be responsible for managing the new subsidiary, Ultivue EMEA Srl, located in Milan, Italy. “The establishment of a European subsidiary provides an excellent structure to support Ultivue’s expanded commercial activities across Europe and engage deeply and efficiently with the biomedical community,” said Philippe Mourere, Ultivue’s Senior Vice President of Commercial Operations. “Ultivue will capitalize on Luigi’s demonstrated success leading both Life Science and Diagnostics activities to continue driving strong execution of its business plan.” Luigi Pirovano has more than 30

Seoul Semiconductor Made Global Distributor Stop Selling Everlight Product in Japan21.2.2019 14:00:00Pressemelding

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) (“Seoul”), a leading global innovator of LED products and technology, announced that it has concluded a patent infringement lawsuit seeking an injunction on the sales of certain LED product sold by Mouser Electronics (“Mouser”). The accused LED product was manufactured by Everlight Electronics Co., Ltd. (“Everlight”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005040/en/ Seoul Semiconductor's Headquarters in Korea (Photo: Business Wire) In February 2018, Seoul filed a patent infringement lawsuit with the Tokyo District Court, accusing the LED product manufactured by Everlight and sold by Mouser of infringing an LED patent of Seoul’s affiliate. Mouser agreed not to export the accused Everlight LED product in Japan, and Seoul therefore agreed to withdraw the lawsuit. The patented technology involved in this litigation serves to efficiently extract light emitted from the i

NTT DATA Launches Advanced 3D Digital Map Package for 5G Network Planning21.2.2019 14:00:00Pressemelding

NTT DATA (TOKYO:9613), a leading IT services provider, announced today its launch of “AW3D Telecom for 5G,” an advanced 3D digital map package that leverages high-quality satellite imagery for the planning of fifth-generation (5G) wireless networks, effective immediately. AW3D for 5G is expected to be used by telecom carriers, network vendors and IoT companies engaged in businesses involving 5G networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005320/en/ Images of AW3D Telecom for 5G (Graphic: Business Wire) Commercial 5G services via fixed wireless access networks launched in the USA in 2018 and will begin operating in Japan, South Korea, the UK and Australia in 2019. Accurate 3D models are crucial for designing 5G networks, which use millimeter-spectrum waves that are highly sensitive to interference from natural and manmade objects. Buildings, trees, bridges, flyover roads, etc. need to be expressed precisely

Universal Laser Systems Maximizes Material Compatibility in New ULTRA 9 Platform21.2.2019 13:05:00Pressemelding

With the increasing use of advanced materials in industrial applications from aerospace to medical devices comes a growing need for innovation in material conversion technology. Developments in laser processing aim to overcome the limitations of existing technology and push the boundaries of how materials can be used. To this end, Universal Laser Systems has released a platform with unprecedented material processing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005340/en/ ULTRA 9 laser platform (Photo: Business Wire) The new ULTRA 9 Platform is designed to perform laser cutting, laser ablation, and laser surface modification. When configured with patented MultiWave Hybrid™ technology, it can combine the laser energy of up to three wavelengths – 9.3 µm (CO2), 10.6 µm (CO2), and 1.06 µm (fiber) – by independently controlling each spectral component of the beam. The user is able to select the ideal waveleng